<DOC>
	<DOCNO>NCT00095797</DOCNO>
	<brief_summary>Phase I trial study effectiveness XK469R treat patient refractory hematologic cancer . Drugs use chemotherapy , XK469R , work different way stop cancer cell divide stop growing die</brief_summary>
	<brief_title>XK469R Treating Patients With Refractory Hematologic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine dose-limiting toxicity , maximum tolerate dose , recommend phase II dose XK469R patient refractory hematologic malignancy . II . Determine pharmacokinetics drug patient . SECONDARY OBJECTIVES : I . Determine presence genetic variation potentially affect XK469R disposition patient treat drug . OUTLINE : This open-label , dose-escalation , multicenter study . Patients receive XK469R IV 30-60 minute day 1 , 3 , 5 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos XK469R maximum tolerate dose ( MTD ) determine . The MTD define dose least 2 6 patient experience dose-limiting toxicity . A total 12 patient receive treatment MTD . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Eosinophilic , Acute</mesh_term>
	<mesh_term>Leukemia , Basophilic , Acute</mesh_term>
	<criteria>Diagnosis 1 follow relapsed refractory hematologic malignancy potentially curative therapy option exhaust : Acute myeloid leukemia* ( AML ) ( nonM3 ) Acute lymphoblastic leukemia* Myelodysplastic syndromes* , include follow : Refractory anemia excess blast ( RAEB ) RAEB transformation Chronic myelomonocytic leukemia transformation* ( CMMLt ) ≥ 10 % peripheral blood/bone marrow blast Chronic myelogenous leukemia blast crisis* ( CMLBC ) Chronic lymphocytic leukemia Rai stage IIIIV Failed prior fludarabinebased therapy ≥ 1 therapy Fludarabine failure define failure achieve partial response complete response ( CR ) least 1 fludarabinecontaining regimen ; disease progression fludarabine ; disease progression within 6 month response fludarabine Not candidate autologous allogeneic stem cell transplantation ( SCT ) Patients previously untreated AML , MDS , CMMLt consider inappropriate candidate , refuse , standard induction chemotherapy due old age concurrent medical condition eligible No known CNS disease Performance status ECOG 02 See Disease Characteristics Bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST ALT &lt; 5 time ULN Creatinine &lt; 1.5 time ULN No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Not pregnant nursing Fertile patient must use effective contraception No ongoing active infection No psychiatric illness social situation would preclude study compliance No history allergic reaction attribute compound similar chemical biologic composition XK469R No uncontrolled illness HIVpositive patient allow provided CD4 count normal AIDSdefining disease No prior allogeneic SCT No concurrent prophylactic hematopoietic colonystimulating factor More 7 day since prior cytotoxic chemotherapy ( except hydroxyurea ) More 7 day since prior radiotherapy No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent No concurrent antileukemia agents No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>